Key Summary
- Orbit Pharma Limited is recalling a specific batch of Cyclizine Lactate 50 mg/ml solution for injection.
- It is being recalled due to Good Manufacturing Practice deficiencies at the manufacturing site.
- Healthcare providers must stop dispensing the affected batch immediately and return all remaining stock to their supplier.
The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a Class 3 Medicines Recall for Orbit Pharma Limited’s Cyclizine Lactate 50 mg/ml solution for injection.
The recall is being undertaken as a precautionary measure following the identification of deficiencies in Good Manufacturing Practice (GMP) at the manufacturing site.
Out of caution, the manufacturer is actively removing the affected stock from the supply chain.
Healthcare professionals and pharmacy teams are advised to stop supplying the affected batch immediately.
All remaining physical stock must be quarantined to prevent further use and returned to the supplier using their approved returns process.
No further action is required by patients, as this recall is being managed entirely at the pharmacy and wholesaler level.
